Erythropoietin (EPO) has received growing attention because of its neuroregenerative properties. Preclinical and clinical evidence supports its therapeutic potential in brain conditions like stroke, multiple sclerosis, and schizophrenia. Also, in Friedreich ataxia, clinical improvement after EPO therapy was shown. The aim of this study was to assess possible therapy-associated brain white matter changes in these patients.
Introduction
EPO has received considerable attention because of its neuroprotective properties, 1, 2 and there is evidence from animal studies pointing to a neuroregenerative potential. [3] [4] [5] [6] Friedreich ataxia (FRDA) is the most common inherited ataxia in those of Western European descent, and is caused by an intronic GAA triplet repeat expansion in the Frataxin gene (FXN; OMIM606829) on chromosome 9q13. 7, 8 Larger GAA expansions are associated with earlier age of onset and greater clinical severity. 9 Frataxin is a small mitochondrial protein involved in iron metabolism, and its deficiency leads to mitochondrial dysfunction and oxidative stress. 8 Expression varies between tissues. In FRDA, the primary sensory neurons are specifically affected, which results in atrophy of the spinal cord's dorsal column and spinocerebellar tracts, which carry the proprioceptive information for the cerebellum. 10 Magnetic resonance imaging (MRI) in FRDA has revealed volume loss in the spinal cord, brainstem, cerebellum, and optic chiasm. [11] [12] [13] [14] DTI has shown white matter (WM) changes including decreased fractional anisotropy (FA) and/or higher Mean Diffusivity (MD). These changes were present in the brainstem and cerebellum, but also in supratentorial regions like the optic radiation. [15] [16] [17] Diffusivity indices also correlated with number of triplet repeats, duration of illness, and scores of clinical severity. 16, 17 There is evidence that EPO could be an effective treatment in FRDA: Sturm et al found that recombinant human EPO (rhuEPO) increases Frataxin levels in isolated lymphocytes from FRDA patients in vitro. 18 Subsequently, significant increase in Frataxin levels and clinical improvement in FRDA patients treated with rhuEPO were shown. 19, 20 age in years at study entry; M, male; F, female; GAA repeats, number of GAA trinucleotide repeats on the shorter allele; DD, disease duration in years; SARA, scale for the assessment and rating of ataxia; FARS, Friedreich ataxia rating scale; Pre, before treatment with rhuEPO; Post, after treatment with rhuEPO; therapy duration with rhuEPO in months.
FRDA, 16, 17 we used DTI in this study to test for possible diffusivity changes in FRDA patients after treatment with rhuEPO.
Methods
Twelve patients with an established diagnosis of FRDA were included in the original clinical study. 19 Demographic and clinical variables are given in Table 1 . Exclusion criteria (described in detail elsewhere 19, 20 ) were all conditions incompatible with EPO treatment, particularly hemoglobin levels above 17 mg/dl and a history of thrombosis.
All diagnostic and therapeutic interventions were performed according to the Declaration of Helsinki and the recommendations of the local Ethics Committee and Security Board after obtaining written informed consent from the patients.
Study Design
In an open-label, phase II, proof-of-concept study, FRDA patients received 5,000 IU rhuEPO subcutaneously 3 times a week for 2 months. The primary outcome measure was the serum concentration of Frataxin. 19 Thereafter, 10 out of these 12 patients entered a 6 months follow-up study and received 2,000 IU rhuEPO 3 times weekly. 20 The rhuEPO dose reduction was due to reported side effects (transient mental agitation, as well as raised hemoglobin and hematocrit levels). Two patients (see Table 1 ) chose not to enter the follow-up study and consequently received rhuEPO only during the initial 2 months. The primary outcome measures for this follow-up study were 2 clinical rating scores, the FRDA Rating Scale (FARS) 21 and the Scale for the Assessment and Rating of Ataxia (SARA). 22 Safety was assessed by biweekly measurement of hematocrit and hemoglobin as well as erythrocyte, reticulocyte, and thrombocyte counts.
MRI Acquisition
MRI was performed before therapy (baseline) and after 10-12 months (follow-up). All participants were scanned on the same 1.5 Tesla MRI scanner (Magnetom Vision; Siemens Medical Solutions, Erlangen, Germany) using a standard circularpolarized head coil. Brain DTI was acquired in axial orientation using a diffusion-weighted spin-echo single-shot echoplanar imaging sequence with diffusion encoding in 6 directions (TE = 94 ms, TR = 6,000 ms, FOV = 256, matrix size of 128 × 128, 35 contiguous axial slices with 3 mm thickness, b values 0, and 1,000 s/mm 2 ). MRI scans were evaluated by an experienced radiologist (K.E.) to rule out structural abnormalities or artifacts. Two patients had to be excluded because of claustrophobia and another patient due to movement artifacts on MRI.
Tract-Based Spatial Statistics (TBSS)
To test for longitudinal diffusivity changes, we performed voxelwise statistical analysis using TBSS, part of the Oxford Center for Functional MRI of the Brain (FMRIB) Software Library (FSL). 23 First, the diffusion data were corrected for effects of motion and eddy currents through affine registration to the b0 volume. This was done using FMRIB's Linear Image Registration Tool, also part of FSL. Diffusion gradients were rotated accordingly. After noise filtering, the images were skull-stripped with the Brain Extraction Tool (also part of FSL). Next, diffusion tensors were estimated using a weighted least squares method in Slicer (slicer.org), and FA maps were computed for all subjects.
Within the TBSS pipeline, all FA images were nonlinearly registered to a single subject. This subject was chosen automatically such that the amount of deformation required for all the other subjects was minimal.
All FA volumes were then averaged and the resulting mean FA image underwent a thinning process leading to the extraction of the skeleton, representing the central course of WM tracts. 23 In order to include only voxels clearly located in WM, this skeleton was thresholded (FA >.3). This threshold is slightly higher than the default threshold of .2, but is also recommended in the original TBSS publication. 23 We chose to use the higher threshold because it yielded a skeleton more clearly restricted to WM, which should help avoid partial volume effects.
Each subject's registered FA data were then projected onto this skeleton.
On these data, we applied a permutation-based voxel-wise paired t-test (5,000 permutations) using Randomise, also part of FSL. 24 The significance threshold was set to P < .05, family-wise error (FWE) corrected for multiple comparisons. 24 The MD, axial diffusivity (D||), radial diffusivity (D ⊥ ), and b0 images were analyzed using the same methodology: we applied the nonlinear warps obtained from the FA registrations and the skeleton projection and performed the same permutation-based test.
In a secondary analysis, we computed Spearman's correlation coefficient between longitudinal change in clinical scores (FARS and SARA) and longitudinal change in DTI parameters, averaged over all significant voxels from the main analysis. This nonparametric correlation coefficient was used due to the ordinal nature of the clinical scores and the small sample size. Fig 1. (A, B) Areas of significant increase in FA (red-yellow) and D|| (blue) after therapy with rhuEPO in patients with FRDA. Significance threshold was set to P < .05, FEW corrected. In the background, the TBSS skeleton is shown in green, superimposed on a T1-weighted image. Images follow the radiological convention (right hemisphere is shown on the left). Slices shown are at X = 12, Y = 10, and Z = 37 in MNI space. (C) Absolute values of FA and AD before and after rhuEPO therapy for each patient. For this graph, FA and AD were averaged over all voxels that showed a significant longitudinal increase in the respective diffusivity measure.
Results
Comparing scans before and after treatment with rhuEPO, we observed widespread and bilateral FA increases (P < .05, FWE corrected), including the frontal, parietal, temporal, and occipital lobes as well as the diencephalon and mesencephalon, but excluding the pons, cerebellum, and medulla oblongata. Increases in D|| were similarly distributed but less pronounced, largely excluding the temporal and occipital lobes (see Fig 1) . These changes in FA and D|| were attended by unchanged MD, D ⊥ , and b0 values throughout the entire brain.
In the correlational analyses, we did not detect correlations between longitudinal DTI changes and changes in SARA or FARS.
Discussion
To the best of our knowledge, this is the first study showing extensive FA increase in patients with a neurodegenerative disease, upon administration of a drug aimed to be neuroregenerative.
FA, MD, D||, and D
⊥ are widely used measures for assessing WM in neurodegenerative processes. In most cases, these studies have reported decreased FA (often attended by increased MD and RD), for example, in FRDA, 15 Huntington's disease 25 and Alzheimer's disease. 26 In the case of D||, both decreases and increases have been reported in neurodegeneration. In some of the above-cited studies where FA was reduced, both D|| and D ⊥ were found increased, but with stronger increase of the latter. 15, [25] [26] [27] In contrast, D|| decline over time was observed in Huntington's. 28 Even in the case of FA, single studies have reported increases associated with pathological conditions or reduced functioning, which was primarily interpreted as reflecting reduced fiber branching or crossing. 29 Overall, while we cannot exclude this possibility, it appears unlikely that the longitudinal FA and D|| increases in our study reflect ongoing neurodegeneration, since these increases included, for example, the body of the corpus callosum, a highly ordered tract, where no fiber crossing is expected.
Regarding normal aging, a recent study focusing on the corpus callosum revealed increasing FA and decreasing MD during childhood and early adolescence, with FA values peaking from 21 to 29 years. 30 As 5 of the participants in our study were within this particular age range, we considered the possibility that the increase in FA could be merely due to ongoing development. This, however, appears unlikely, since FA increase in early adulthood is combined with prolonged decrease of D||, 30 whereas D|| in our patients increased significantly.
In combined histopathological-imaging studies in animals, axonal and myelin injury were found to correlate with elevated D|| and reduced D ⊥ , respectively, 31 and the reverse held true for regeneration. 32 However, there are recent data indicating that the DTI-histology relationship may be more complex. For example, 2 recent studies in humans found axonal density to be correlated with FA and D ⊥ , but not significantly with D||. 33, 34 In the light of these reports, one can only speculate about the histological basis of the changes seen in our study, while axonal changes appear as a possible candidate. Since iron metabolism is affected in FRDA, 8 we sought to rule out the possibility that ongoing iron deposition may have affected the diffusion-weighted data due to signal changes in the b0 images. However, comparison of these b0 images at baseline and follow-up did not reveal significant or trend-level alterations. Hence, iron deposition is unlikely to explain our findings.
EPO and its derivatives have come into focus as promising candidates for the treatment of various brain conditions. There has been a wealth of preclinical studies and also some encouraging clinical trials, particularly in ischemic stroke, multiple sclerosis, and schizophrenia (reviewed in Sargin et al (2010) 35 ). EPO and EPO receptors are expressed in the brain during development and adulthood. 36 As mentioned, several animal studies have demonstrated beneficial effects of EPO administration after traumatic brain injury or ischemia. [3] [4] [5] [6] In the context of our DTI findings, it is particularly noteworthy that EPO increased oligodendrogenesis and reduced WM damage after ischemia in rats. 3 Moreover, EPO administered after traumatic brain injury leads to higher glucose levels and lower lactate levels. 37 In FRDA patients, PET studies have shown that glucose metabolism is initially increased in various brain regions, but decreases again with clinical severity. 38 Therefore, the impact of EPO as measured in our study could also be related to an improvement of energy supply.
Regardless of the exact biological mechanism, we speculate that the changes seen are reflective of disease-unspecific EPO effects, which is supported by 2 observations: First, significant effects were located only in regions that are not primarily affected in FRDA, ie, not in the medulla, pons, and cerebellum. One could speculate that these regions have less regenerative potential and are therefore less susceptible to the unspecific "positive" effects of EPO.
Second, we could not detect significant correlations between changes in clinical and diffusivity parameters, which is also likely related to the small sample size and resulting limited power in our study.
Unfortunately, there are no longitudinal studies assessing the development of DTI parameters in patients with FRDA specifically. Also, since our study lacks a placebo group, we consequently were not able to assess how diffusion parameters would have changed without therapy.
Additional limitations of this study include using a DTI acquisition protocol with only 6 directions of diffusion gradients, and the relatively small number of study participants.
Conclusion
In this exploratory study, TBSS revealed extensive WM changes in patients with FRDA following therapy with rhuEPO. This finding supports the exciting potential of rhuEPO for neuroprotection and-regeneration in humans. Additionally, our findings, in combination with previously published results, 16, 17 support the potential of diffusivity parameters to act as valuable biomarkers in the assessment of disease progression and therapeutic response.
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